《新股》大行科工(02543.HK)公開發售超購7,557倍 一手中率僅0.02%
大行科工(02543.HK)公布招股結果,香港公開發售接獲7,558.4倍認購,一手(100股)中籤率僅0.02%。國際發售錄得21.65倍認購。股份預期周二(9日)上市。
內地最大折疊自行車公司大行科工是次擬全球發售792萬股,香港公開發售佔10%。招股價49.5元,集資淨額3.42億元。四名基石投資者安聯環球投資亞太、大灣區基金管理、Harvest及維科技術(600152.SH)控股的維科香港合共認購201.38萬股,佔發售總數25.43%,禁售於2026年3月8日結束。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.